While Valneva has reviewed its 2025 financial results and confirmed guidance for 2026, the company’s focus remains singularly fixed on an upcoming clinical milestone. The Phase 3 readout for its Lyme disease vaccine candidate, VLA15, represents the pivotal event for which the firm has been strategically positioning itself by streamlining its core business operations.
Liquidity and Debt Management Shows Improvement
A positive development in Valneva’s 2025 report is the improved management of its cash position. The operational cash burn decreased to €52.9 million, down from €67.2 million in 2024 and a significant reduction from €202.7 million in 2023. The company ended the year with €109.7 million in liquidity and has successfully refinanced its debt obligations.
2025 Financials Require Contextual Understanding
At first glance, a net loss of €115.2 million for 2025 appears stark compared to the prior year’s loss of just €12.2 million. This disparity is largely attributable to a one-time event in 2024, when Valneva recorded a net gain of €90.8 million from the sale of a Priority Review Voucher for IXCHIQ®. The absence of this benefit in 2025 accounts for the majority of the year-over-year difference.
Total revenue of €174.7 million fell within the projected range. A closer examination reveals a deliberate strategic shift: third-party product sales declined as planned by 42%, while proprietary brands showed growth. Sales of IXIARO®/JESPECT® increased by 4.6% to €98.4 million. Revenue for IXCHIQ® doubled to €8.4 million, driven in part by efforts to combat a Chikungunya outbreak on La Réunion.
Should investors sell immediately? Or is it worth buying Valneva?
Operational Challenges and Regulatory Hurdles
The year was not without its difficulties. The gross margin for DUKORAL® fell to 33.3%, impacted by batch failures in the fourth quarter. IXCHIQ® posted a negative gross margin, primarily due to inventory write-downs of €8.5 million, mostly related to the termination of a supply agreement with the Serum Institute of India.
The company also faces a regulatory issue. Following an FDA inspection, the agency currently cannot approve the Almeida manufacturing site for IXIARO®. Valneva is working to address the cited observations, and the US market will continue to be supplied from its Manson site in the interim.
Pipeline and Outlook: All Eyes on VLA15
For 2026, Valneva anticipates total revenue between €155 million and €170 million. However, the true focal point is the company’s development pipeline. The Phase 3 clinical trial results for VLA15 are expected in the first half of 2026. Positive data would trigger subsequent regulatory filings by partner Pfizer, potentially unlocking initial milestone payments of $143 million for Valneva, along with future sales royalties ranging from 14% to 22%.
A successful outcome that justifies regulatory approval would fundamentally reshape the company’s valuation. Until that point, Valneva’s portfolio of three approved travel vaccines continues to fund its clinical work—a crucial, if limited, financial foundation for the high-stakes development program ahead.
Ad
Valneva Stock: Buy or Sell?! New Valneva Analysis from March 21 delivers the answer:
The latest Valneva figures speak for themselves: Urgent action needed for Valneva investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 21.
Valneva: Buy or sell? Read more here...
